帕尔福齐亚(Peanut (Arachis hypogaea) Allergen Powder-dnfp) - 在研适应症：花生过敏_专利_临床

概要

基本信息

药物类型

变应原提取物

别名

花生过敏原粉、AR101、Palforzia

靶点-

作用机制

免疫调节剂

治疗领域

免疫系统疾病

在研适应症

花生过敏

非在研适应症-

原研机构

Aimmune Therapeutics, Inc.

在研机构

Aimmune Therapeutics, Inc.Aimmune Therapeutics Ireland Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2020-01-31),

花生过敏

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

关联

18

项与帕尔福齐亚相关的临床试验

EUCTR2017-001334-26-DE / Unknown status临床3期

A MULTICENTER, OPEN-LABEL, LONGER-TERM STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY - Longer-term Study of AR101 CODIT™

开始日期2019-02-12

申办/合作机构

Aimmune Therapeutics, Inc.

NCT03736447 / Completed临床3期

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)

The purpose of this study is to determine the efficacy and safety of AR101 in peanut-allergic children aged 1 to < 4 years.

开始日期2018-12-27

申办/合作机构

Aimmune Therapeutics, Inc.

NCT03703791 / Terminated临床3期

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adolescents: Real World, Open Label, Quality of Life Study

To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in combination with standard of care (peanut avoidance, education) versus standard of care alone in peanut-allergic subjects aged 4 to 17 years.

开始日期2018-10-24

申办/合作机构

Aimmune Therapeutics, Inc.

100 项与帕尔福齐亚相关的临床结果

登录后查看更多信息

100 项与帕尔福齐亚相关的转化医学

登录后查看更多信息

100 项与帕尔福齐亚相关的专利（医药）

登录后查看更多信息

29

项与帕尔福齐亚相关的文献（医药）

2023-12-13·Cureus

Palforzia for Peanut Allergy: A Narrative Review and Update on a Novel Immunotherapy

Review

作者: Ahmadzadeh, Shahab ; Shekoohi, Sahar ; Varrassi, Giustino ; Plaisance, Connor J ; Borne, Grant E ; Myrcik, Dariusz ; Wagner, Maxwell J ; Daniel, Charles P ; Nolen, Alexandra ; Kaye, Alan D ; Kelkar, Rucha A

With Palforzia appearing as the first oral immunotherapy for patients with peanut allergy, the present investigation aims to summarize recent clinical trials, the mechanism of dosing, and the real-world usage of this novel therapy. Palforzia offers a new avenue for treating the human allergic response in previous immune modulation refractory patients or patients who have undergone immune environment sensitivity testing, which allows for more specialized treatment. Current studies are focusing on certain age groups that have been shown to be more receptive to treatment. Further, studies are tailoring oral immunotherapy treatment alongside other immune modulators to elicit greater targeted immune tolerance. With an increasing prevalence of patient allergies, many questions remain surrounding the optimization of therapies in reaching therapeutic goals. Overall, Palforzia offers a hopeful treatment for peanut-allergic patients to attenuate their immune response while furthering research in related therapies.

2023-08-01·The journal of allergy and clinical immunology. Global

Long-term safety and immunologic outcomes of daily oral immunotherapy for peanut allergy.

Article

作者: Bird, J Andrew ; Nilsson, Caroline ; Brown, Kari ; Pham, Trinh ; Tilles, Stephen ; Assa'ad, Amal ; du Toit, George

Background:

Oral immunotherapy containing peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) (Palforzia [Aimmune Therapeutics, Brisbane, Calif]) for 9 to 12 months resulted in higher tolerated amounts of peanut protein in PTAH-treated individuals aged 4 to 17 years with peanut allergy than in placebo-treated participants.

Objective:

We aimed to describe additional long-term pooled safety data and changes in peanut sensitization markers from baseline through approximately 5 years of treatment.

Methods:

The results from 6 clinical trials of PTAH (3 controlled and 3 open-label extension studies [N = 1227]) were pooled, and analysis of safety outcomes and immunologic data was performed. The PTAH doses were administered sequentially as follows: initial dose escalation (dose increased to 6 mg over 2 days), updosing (dose increased every 2 weeks to 300 mg for a minimum of 6 months), and maintenance dosing (300 mg per day).

Results:

There was a trend toward decreased adverse events (AEs) at years 1 and 2 that was maintained up to 5 years, with 94% of patients experiencing mild or moderate AEs and only 13% discontinuing PTAH use because of AEs overall. Gastrointestinal symptoms were the most commonly reported treatment-related AEs. A downward trend in systemic allergic reactions was also reported. PTAH treatment resulted in reduced levels of peanut-specific IgE after the first year and increased levels of peanut-specific IgG4, with a lowered peanut-specific IgE:IgG4 ratio. A reduction in median peanut skin prick test wheal diameter was observed (11.50 mm at baseline vs 5.75 mm at year 5).

Conclusion:

Long-term immunomodulation without any new safety signals was reported with PTAH immunotherapy in the largest safety data set and longest treatment duration for oral immunotherapy published to date.

2023-03-13·Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials.

Article

作者: Ryan, Robert ; Blumchen, Katharina ; Norval, David ; Zeitler, Stefan ; Beyer, Kirsten ; Butovas, Sergejus ; Du Toit, George ; Klimek, Ludger ; Vogelberg, Christian ; Kleinheinz, Andreas ; Anagnostou, Aikaterini

PURPOSE:

Peanut allergy and its current management, involving peanut avoidance and use of rescue medication during instances of accidental exposure, are burdensome to patients and their caregivers and can be a source of stress, uncertainty, and restriction. Physicians may also be frustrated with a lack of effective and safe treatments other than avoidance in the current management of peanut allergy. Efficacy, determined using double-blind, placebo-controlled food challenges (DBPCFCs), of oral immunotherapy with peanut (Arachis hypogaea) allergen powder-dnfp (PTAH; Palforzia^®) was demonstrated versus placebo in children and adolescents aged 4 to 17 years in multiple phase 3 trials; continued benefit of PTAH was shown in a follow-on trial. The DBPCFC is a reproducible, rigorous, and clinically meaningful assessment accepted by regulatory authorities to evaluate the level of tolerance as an endpoint for accidental exposures to peanut in real life. It also provides useful clinical and patient-relevant information, including the amount of peanut protein an individual with peanut allergy can consume without experiencing dose-limiting symptoms, severity of symptoms, and organs affected upon ingestion of peanut protein. We explored symptoms of peanut exposure during DBPCFCs from phase 3 and follow-on trials of PTAH to further characterize treatment efficacy from a perspective relevant to patients, caregivers, and clinicians.

METHODS:

Symptom data recorded during screening and/or exit DBPCFCs from participants aged 4 to 17 years receiving PTAH or placebo were examined post hoc across three PTAH trials (PALISADE [ARC003], ARC004 [PALISADE follow-on], and ARTEMIS [ARC010]). The maximum peanut protein administered as a single dose during DBPCFCs was 1000 mg (PALISADE and ARTEMIS) and 2000 mg (ARC004). Symptoms were classified by system organ class (SOC) and maximum severity. Endpoints were changes in symptom severity and freedom from symptoms (ie, asymptomatic) during DBPCFC. Relative risk (RR) was calculated for symptom severity by SOC and freedom from symptoms between groups; descriptive statistics were used to summarize all other data.

RESULTS:

The risk of any respiratory (RR 0.42 [0.30-0.60], P < 0.0001), gastrointestinal (RR 0.34 [0.26-0.44], P < 0.0001), cardiovascular/neurological (RR 0.17 [0.08-0.39], P < 0.001), or dermatological (RR 0.33 [0.22-0.50], P < 0.0001) symptoms was significantly lower in participants treated with PTAH versus placebo upon exposure to peanut at the end of the PALISADE trial (ie, exit DBPCFC). Compared with placebo-treated participants (23.4%), the majority (76.3%) of PTAH-treated participants had no symptoms at the exit DBPCFC when tested at the peanut protein dose not tolerated (ie, reactive dose) during the screening DBPCFC. Significantly higher proportions of PTAH-treated participants were asymptomatic at doses ≤ 100 mg in the exit DBPCFC compared with placebo-treated participants (PALISADE: 69.35% vs 12.10%, RR 5.73 [95% confidence interval (CI) 3.55-9.26]; P < 0.0001; ARTEMIS: 67.42% vs 13.95%, RR 4.83 [95% CI 2.28-10.25]; P < 0.0001); findings were similar at peanut protein doses ≤ 1000 mg (PALISADE: RR 15.56 [95% CI 5.05-47.94]; P < 0.0001; ARTEMIS: RR 34.74 [95% CI 2.19-551.03]; P < 0.0001). In ARC004, as the period of PTAH maintenance became longer, greater proportions of participants were asymptomatic at doses of peanut protein ≤ 1000 mg in the exit DBPCFC (from 37.63% after ~ 6 months of maintenance treatment [exit DBPCFC of PALISADE] to 45.54% after ~ 13 months and 58.06% after ~ 20 months of overall PTAH maintenance treatment).

CONCLUSIONS:

PTAH significantly reduced symptom severity due to exposure to peanut, which is clinically relevant. When exposed to peanut, participants with peanut allergy treated with PTAH rarely had moderate or severe respiratory or cardiovascular/neurological symptoms. Oral immunotherapy with PTAH appears to reduce frequency and severity of allergic reactions in individuals with peanut allergy after accidental exposure to peanut and may enable them and their families to have an improved quality of life. Trial registration ClinicalTrials.gov, NCT02635776, registered 17 December 2015, https://clinicaltrials.gov/ct2/show/NCT02635776?term=AR101&draw=2&rank=7 ; ClinicalTrials.gov, NCT02993107, registered 08 December 2016, https://clinicaltrials.gov/ct2/show/NCT02993107?term=AR101&draw=2&rank=6 ; ClinicalTrials.gov, NCT03201003, registered 22 June 2017, https://clinicaltrials.gov/ct2/show/NCT03201003 ? term = AR101&draw = 2&rank = 9.

75

项与帕尔福齐亚相关的新闻（医药）

2024-05-16

·Pharmaceutical Technology

Food Allergy Awareness Week 2024: How can new treatments target an unmet need?

GlobalData epidemiologists forecast that the food allergy market is forecast to reach $2.7bn by 2030. Credit: Alphavector via Shutterstock. Food Allergy Awareness Week, which runs from 12 to 18 May this year, is drawing attention to the innovations under development for treating food allergies. Earlier this year, a breakthrough in the food allergy space was when Novartis and Roche’s Xolair (omalizumab) won US Food and Drug Administration (FDA) approval. Initially approved for asthma in 2003, its label was expanded, making it the first FDA-approved drug to reduce allergic reactions in people with IgE-mediated food allergies. This classification includes food-based allergens such as peanuts, milk, eggs, wheat, cashew nuts, hazelnut, or walnut. Still, despite the observed efficacy with Xolair, the drug can take a few months to start working properly, highlights Jessica Grossman, CEO of San-Francisco-based allergy company IgGenix. “Xolair is a great step forward for the allergic community. However, there still are some limitations if it takes 16 weeks to work,” she said. IgGenix is developing an IgG4 monoclonal antibody-based therapeutic called IGXN001 specifically for peanut allergies. The candidate is expected to protect against accidental exposure to peanut allergens within days of administration. See Also: Cutting losses in drug manufacturing: A new era in fill-finish technology CinDome Pharma secures $40m to advance gastroparesis treatment The company, which spun out of Stanford University in 2019, closed a $40m Series B financing round in February 2024 to advance IGXN001 to the clinic. The funding round was led by Alexandria Venture Investments and Eli Lilly and Company. Grossman said the company is initiating a Phase I clinical trial later this year following positive preclinical pharmacokinetic (PK) studies: “In our animal studies, the PK of the antibody is modelled to be about 30 days in humans. What we’re hoping that means in humans is that that the antibody will have a relatively long PK or a relatively long concentration time in the blood, longer than Xolair.” The Phase I trial start, targeting late Q3 or Q4 2024, will measure safety as the primary endpoint in otherwise healthy individuals with peanut allergies. The trial design will involve a single-ascending dose across three cohorts and will also examine the blood concentration PK of IGXN001. “We are thinking from some of our modelling [data] that we’ll be able to dose every other month, which would be a big advantage,” added Grossman. There is certainly innovation in the peanut allergy space, highlighted by Intrommune Therapeutics’ desensitisation immunotherapy , which is delivered as toothpaste. The company announced positive results from the Phase I OMEGA clinical trial (NCT04603300) investigating INT301 in November 2023. Data highlighted that 100% of those treated with the toothpaste consistently tolerated the highest dose of the allergen. There are also approved medications to treat peanut allergies, including Palforzia (arachis hypogaea) . Nestlé acquired Palforzia through its $2.6bn takeover of Aimmune Therapeutics in 2020. However, Nestlé shifted the drug to Swiss biopharma Stallergenes Greer in September 2023, following a “ slower than expected adoption by patients and healthcare professionals”. Palforzia needs to be taken daily and carries a warning for anaphylaxis on its label. Grossman commented on oral medications in the young patient population: “Generally, oral immunotherapy isn’t for them. There’s definitely an unmet need in the young adult population.” DBV Technologies , which is developing an allergen patch called Viaskin, has faced multiple challenges in getting it to the market in the past few years, following a clinical hold and the FDA requesting additional data in April 2023. According to a report on GlobalData’s Pharma Intelligence Center, the food allergy market was valued at $213.9m in 2020 globally and is forecast to reach $2.7bn by 2030, growing at a compound annual growth rate (CAGR) of 28.8%. In the eight major markets (UK, US, Germany, France, Italy, Spain, Australia, and Canada), GlobalData epidemiologists forecast that there will be more than seven million peanut allergy cases in 2027.

临床1期上市批准免疫疗法临床结果并购

2024-02-23

·蒲公英Ouryao

FDA批准了一种可以解决多种食物过敏的药物

转自：法迈思2024年2月16日，美国食品和药物管理局批准 Xolair (奥马珠单抗) 注射剂用于某些成人和 1 岁或以上儿童的免疫球蛋白 E 介导的食物过敏，以减少过敏反应 (I 型)，包括降低可能发生的过敏反应的风险意外接触一种或多种食物。服用 Xolair 的患者必须避免接触对其过敏的食物。Xolair 旨在重复使用以降低过敏反应的风险，并且不被批准用于包括过敏反应在内的过敏反应的立即紧急治疗。Xolair 最初被 2003 年批准用于治疗某些患者的中度至重度持续性过敏性哮喘。Xolair 还被批准用于治疗某些患者的慢性自发性荨麻疹和慢性鼻鼻窦炎伴鼻息肉。“新批准的 Xolair 的使用将提供一种治疗选择，以降低某些 IgE 介导的食物过敏患者中有害过敏反应的风险，” Kelly Stone博士。他是 FDA 药物评估和研究中心肺病、过敏和重症监护部门的副主任。“虽然它不会消除食物过敏或允许患者自由食用食物过敏原，但如果发生意外接触，它的重复使用将有助于减少对健康的影响。根据美国疾病控制和预防中心的数据，美国 2021 年近 6% 人患有食物过敏，接触他们过敏的特定食物可能导致潜在的威胁生命的过敏反应(即过敏反应)。目前还没有治疗食物过敏的方法。目前的治疗需要严格避免患者过敏的食物，并在发生意外暴露时及时给予肾上腺素以治疗过敏反应。Palforzia (花生过敏原粉) 是一种口服免疫治疗产品，已批准用于 4-17 岁患者，以减轻意外接触花生可能发生的过敏反应，包括过敏反应，但其益处仅限于花生过敏。Xolair 是 FDA 批准的第一种减少意外暴露后对一种以上食物的过敏反应的药物。Xolair 在减少食物过敏受试者过敏反应方面的安全性和有效性是在一项多中心、双盲、安慰剂对照研究中确定的，该研究涉及 168 名对花生和至少两种其他食物（包括牛奶、鸡蛋、小麦、腰果、榛子或核桃）过敏的儿童和成人受试者（至少 1 岁或以上）。研究人员随机给予受试者 Xolair 或安慰剂治疗 16 至 20 周。Xolair 疗效的主要衡量标准是能够在 16 至 20 周疗程结束时食用单剂量（600 毫克或更多）花生蛋白（相当于 2.5 颗花生）而没有中度至重度过敏症状（例如中度至重度皮肤、呼吸道或胃肠道症状）的受试者百分比。在接受 Xolair 治疗的患者中，68%（110 名受试者中的 75 名）能够食用单剂量的花生蛋白，而没有中度至重度过敏症状（例如，全身荨麻疹、持续咳嗽、呕吐），而接受安慰剂治疗的患者为 6%（55 名受试者中的 3 名）;这些结果对食物过敏的受试者具有统计学意义和临床意义。然而，值得注意的是，接受Xolair治疗的受试者中有17%的花生蛋白耐受量没有显著变化（不能耐受 100 毫克或更多的花生蛋白）。因此，尽管使用 Xolair 进行治疗，但仍有必要继续严格避免过敏原。疗效的关键次要指标是在 16 至 20 周的疗程结束时能够食用单剂量（1,000 毫克或更多）腰果、牛奶或鸡蛋蛋白而没有中度至重度过敏症状的受试者百分比。对于腰果，接受 Xolair 治疗的 42%（64 名受试者中的 27 名）达到了这一目标，而接受安慰剂治疗的这一比例为 3%（30 名受试者中的 1 名）。对于牛奶，接受 Xolair 治疗的 66%（38 名受试者中的 25 名）达到了这一目标，而接受安慰剂治疗的这一比例为 11%（19 名受试者中的 2 名）。对于鸡蛋，接受 Xolair 治疗的 67%（46 名受试者中的 31 名）达到了这一目标，而接受安慰剂治疗的 19 名受试者中只有0%。因此，Xolair 治疗被批准用于某些患有一种或多种 IgE 介导的食物过敏的患者。观察到的 Xolair 最常见的副作用包括引发部位反应和发烧。Xolair带有某些警告和预防措施，例如过敏反应恶性肿瘤，发烧，关节疼痛，皮疹，寄生虫（蠕虫）感染和异常实验室检查。此外，根据 Xolair 给药后发生的过敏反应的上市前和上市后报告，Xolair 还附带了过敏反应的盒装警告，过敏反应可能危及生命。过敏反应发生在 Xolair 首次给药后，但也发生在开始治疗后一年以上。Xolair 只能在配备有过敏反应管理能力的医疗机构中开始使用。对于在医疗机构中耐受初始 Xolair治疗且无全身性过敏反应的特定患者，自我给药（或由护理人员给药）可能是合适的，应与医疗提供者讨论。如果患者已知对 Xolair 或其任何成分有严重超敏反应史，则不应接受 Xolair 治疗。Xolair 未被批准用于过敏反应（包括过敏反应）的即时紧急治疗。Xolair 获得了该适应症的优先审查和突破性疗法认定。FDA 批准了 Xolair 给 genentech。

临床结果临床研究免疫疗法

2024-02-16

·FiercePharma

FDA approves Roche, Novartis' Xolair to prevent severe outcomes from common food allergies

Novartis and Roche's Xolair has been approved by the FDA to prevent severe allergic reactions to common foods such as peanuts, tree nuts, milk, eggs and wheat. People with food allergies finally have a medicine that can help prevent severe outcomes—and it’s a drug that’s been on the market for two decades. The FDA has blessed Roche and Novartis’ Xolair (omalizumab) as the first medicine to reduce allergic reactions that can occur with accidental exposure to certain foods. The drug is approved for people ages 1 year and older with certain allergies. The therapy is for people with IgE-mediated food allergies, a classification that includes 160 foods, the most common of which are peanuts, milk, eggs, wheat, soy and tree nuts. Xolair is not designed to allow patients to freely eat these foods. It just helps them avoid severe reactions, including anaphylaxis, a life-threatening condition that can happen immediately as the immune system releases chemicals that can cause the body to go into shock. There are 3.4 million children in U.S. that have food allergies and more than 40% of them have had at least one severe reaction, according to Roche subsidiary Genentech. Food reactions cause approximately 30,000 emergency room visits each year in the U.S. The approval came just two months after the FDA accepted the companies’ supplemental biologics license application in this indication. After injections of Xolair every two to four weeks—with intervals determined by body weight and serum immunoglobulin E (IgE) level—patients would be protected. Backing the green light are results of a phase 3 trial, which was co-sponsored by the U.S. National Institutes of Health. The phase 3 OUtMATCH study showed that Xolair significantly increased the amount of peanut (primary endpoint) and milk, egg and cashew (secondary endpoints) it took to cause an allergic reaction compared to placebo. Study results showed 68% of patients treated with Xolair for 16 to 20 weeks tolerated at least 600 mg of peanut protein without moderate to severe allergic symptoms, compared to 5% of those treated with placebo. This amount is equivalent to approximately two and a half peanuts, or half a teaspoon of regular peanut butter. Xolair was first approved by the FDA in 2003 for asthma. The drug generated $3.9 billion in sales last year. Xolair works by inhibiting IgE antibodies, which cause chemical reactions that produce inflammation seen in allergy and asthma attacks. In 2018, the FDA granted breakthrough designation for Xolair as a treatment for food allergies. “Many people with food allergies and their loved ones live in constant fear of accidentally coming into contact with the food they are allergic to and the life-threatening allergic reaction,” Reshema Kemps-Polanco, Novartis U.S. chief commercial officer, said in a release. “Today’s approval of Xolair represents a paradigm shift in the way food allergies can be managed.” In September of last year, Nestle sold its peanut allergy drug Palforzia to Stallergenes Greer for an undisclosed sum. In 2020, Palforzia was the first peanut allergy drug approved by the FDA, but its sales never indicated it could reach Evaluate Pharma’s projection of $1.28 billion by 2024. Nestle acquired Palforzia in a $2.1 billion buyout of Aimmune Therapeutics.

临床结果上市批准临床3期并购突破性疗法

100 项与帕尔福齐亚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	帕尔福齐亚	V01AA	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
花生过敏	美国	Aimmune Therapeutics, Inc.	2020-01-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03682770 (CTgov)	临床2期	花生过敏	148	Placebo+AR101 (AR101 Up-dosing Period: Placebo + AR101)	襯廠獵觸糧積餘艱襯觸(憲蓋糧廠齋積築齋鹽蓋) = 鬱鏇築遞製糧鹹鏇範鑰鬱艱膚鏇鏇餘鬱築醖願 (獵窪衊窪獵鑰鏇觸鏇繭, 蓋鹹憲鑰積選選餘憲淵 ~ 鹽選憲鏇製夢餘顧鑰艱) 更多	-	2024-02-07
				Dupilumab+AR101 (AR101 Up-dosing Period: Dupilumab + AR101)	襯廠獵觸糧積餘艱襯觸(憲蓋糧廠齋積築齋鹽蓋) = 夢艱衊繭製廠夢糧膚網鬱艱膚鏇鏇餘鬱築醖願 (獵窪衊窪獵鑰鏇觸鏇繭, 顧繭醖繭壓範築鬱鏇夢 ~ 遞蓋齋窪齋築蓋襯顧觸) 更多
NCT03736447 (POSEIDON, Literature) 人工标引	临床3期	花生过敏	146	PALFORZIA	範鹽餘艱夢遞醖製願鏇(壓簾願餘願繭襯願膚製) = 蓋願鏇憲獵糧窪網遞構繭衊鹹襯鹽選夢醖選鑰 (積鹹鑰遞鹹簾獵艱獵繭 ) 更多	积极	2023-10-23
				Placebo	範鹽餘艱夢遞醖製願鏇(壓簾願餘願繭襯願膚製) = 顧構遞繭積艱願構鑰製繭衊鹹襯鹽選夢醖選鑰 (積鹹鑰遞鹹簾獵艱獵繭 ) 更多
NCT03736447 (CTgov)	临床3期	花生过敏	146	AR101 (AR101)	鬱襯醖鏇糧廠廠壓網簾(膚選淵繭膚觸淵蓋製壓) = 廠築蓋構鹽簾餘顧艱醖鏇衊製鏇鑰鹹網衊網簾 (餘艱餘顧鹹構蓋觸製鑰, 憲膚鑰鏇繭壓範積製衊 ~ 淵膚蓋網淵構鏇艱構獵) 更多	-	2023-03-02
				Placebo+AR101 (Placebo)	鬱襯醖鏇糧廠廠壓網簾(膚選淵繭膚觸淵蓋製壓) = 選膚鑰築艱網構網簾築鏇衊製鏇鑰鹹網衊網簾 (餘艱餘顧鹹構蓋觸製鑰, 選鏇鹽壓廠糧鑰襯觸憲 ~ 範鏇鏇築鑰鹽醖淵鹹窪) 更多
NCT03736447 (POSEIDON, AAAAI2023)	临床3期	花生过敏	146	PTAH	憲鏇製積醖鹽簾鏇遞鏇(選鹹糧顧鬱糧糧壓夢範) = 鬱夢獵鹹壓網襯觸齋鑰壓襯壓鏇構願襯艱網繭 (糧鑰獵襯獵襯壓獵鬱構 ) 更多	积极	2023-02-01
				Placebo	憲鏇製積醖鹽簾鏇遞鏇(選鹹糧顧鬱糧糧壓夢範) = 構齋簾襯範積醖餘憲膚壓襯壓鏇構願襯艱網繭 (糧鑰獵襯獵襯壓獵鬱構 ) 更多
NCT02635776 (CTgov)	临床3期	花生过敏	555	peanut protein+AR101 (AR101)	繭餘製築淵獵範夢觸觸(簾窪醖淵壓鬱鏇獵築衊) = 觸築鏇淵鑰範齋壓鏇網網廠鑰鬱鹹鑰憲鹹壓觸 (襯繭觸獵簾願獵鬱獵顧, 醖鹽網糧艱衊鏇簾壓蓋 ~ 範積憲願網壓築願願齋) 更多	-	2022-03-17
				Placebo (Placebo)	繭餘製築淵獵範夢觸觸(簾窪醖淵壓鬱鏇獵築衊) = 選鹽製艱觸鑰選蓋鹽襯網廠鑰鬱鹹鑰憲鹹壓觸 (襯繭觸獵簾願獵鬱獵顧, 壓積遞糧鹹願簾獵積範 ~ 鏇繭淵鑰艱齋願鏇構淵) 更多
NCT02198664 (CTgov)	临床2期	花生过敏	47	AR101 - Peanut protein capsule (ARC001 Placebo Group)	衊顧鬱鬱鑰鹽鹽艱艱鑰(簾遞範餘觸鏇夢觸鹹艱) = 網築淵襯廠鏇積願廠窪願淵糧餘餘餘鏇淵構窪 (積遞選壓衊願顧觸觸廠, 簾餘廠衊蓋觸齋齋鑰夢 ~ 齋鬱願憲簾願構築繭衊) 更多	-	2021-11-09
				AR101 - Peanut protein capsule (ARC001 AR101 Group)	衊顧鬱鬱鑰鹽鹽艱艱鑰(簾遞範餘觸鏇夢觸鹹艱) = 構鏇鬱簾繭積鏇範簾繭願淵糧餘餘餘鏇淵構窪 (積遞選壓衊願顧觸觸廠, 艱餘餘選顧襯餘構醖齋 ~ 壓壓膚艱選廠餘廠壓網) 更多
NCT03337542 (CTgov)	临床3期	花生过敏	243	AR101	糧顧構繭夢鬱範齋廠簾(廠觸衊衊範選憲網衊遞) = 鏇積窪鑰鑰淵範鬱選繭積築糧築壓衊膚顧艱築 (窪範築選餘範襯憲顧糧, 廠築獵製膚鹽簾網觸範 ~ 鬱衊網鏇網獵遞鹽鏇鹽) 更多	-	2021-11-02
NCT03126227 (CTgov)	临床3期	花生过敏	506	AR101 (AR101 Powder Provided in Capsules)	簾願製獵鹹膚齋艱積襯(遞窪願廠糧鹹鏇蓋鹹構) = 艱艱憲範觸積鹹構簾窪鏇鹽觸鑰淵願窪繭積餘 (簾鏇衊範齋製鏇顧簾觸, 窪願襯網顧顧獵遞鏇鬱 ~ 鏇鹽鬱獵壓壓鹹蓋艱餘) 更多	-	2021-11-02
				Placebo (Placebo Powder)	簾願製獵鹹膚齋艱積襯(遞窪願廠糧鹹鏇蓋鹹構) = 製積構窪醖膚鹽夢醖鬱鏇鹽觸鑰淵願窪繭積餘 (簾鏇衊範齋製鏇顧簾觸, 艱窪襯鏇鬱蓋醖獵襯選 ~ 窪鏇鑰蓋襯艱膚範鏇壓) 更多
NCT01987817 (CTgov)	临床2期	花生过敏	56	AR101 powder provided in capsules (AR101 Powder Provided in Capsules)	窪齋膚鹽窪鏇餘鬱繭膚(齋蓋鑰鬱齋淵繭鹹鏇製) = 鑰衊醖鬱網艱獵衊淵餘鹽淵壓膚鏇鬱齋憲鏇獵 (衊積窪淵鏇鏇糧獵獵構, 夢鹹齋醖憲窪積遞鹹製 ~ 鹽鬱顧鏇壓衊顧繭糧膚) 更多	-	2021-11-02
				Placebo powder provided in capsules (Placebo Powder Provided in Capsules)	窪齋膚鹽窪鏇餘鬱繭膚(齋蓋鑰鬱齋淵繭鹹鏇製) = 繭繭艱繭蓋憲鹽鏇構醖鹽淵壓膚鏇鬱齋憲鏇獵 (衊積窪淵鏇鏇糧獵獵構, 觸窪鹽願膚簾餘醖製蓋 ~ 壓製繭壓繭遞鑰獵糧夢) 更多
NCT03201003 (CTgov)	临床3期	花生过敏	175	AR101 powder provided in capsules & sachets (AR101)	餘範選積艱願鹽襯淵獵(餘齋積範衊窪繭鹽蓋餘) = 願鏇淵簾醖簾鹽蓋鬱餘範壓築範鬱顧觸廠糧鹹 (鹽繭選廠衊淵簾鑰鏇觸, 憲夢鏇衊夢遞夢夢積廠 ~ 遞築顧顧鑰襯製願顧膚) 更多	-	2021-08-03
				Placebo powder provided in capsules & sachets (Placebo)	餘範選積艱願鹽襯淵獵(餘齋積範衊窪繭鹽蓋餘) = 網艱觸鏇獵觸憲觸範齋範壓築範鬱顧觸廠糧鹹 (鹽繭選廠衊淵簾鑰鏇觸, 餘廠廠夢糧鏇餘築鏇糧 ~ 襯艱構糧膚範淵網夢鏇) 更多